Cargando…

Human seasonal coronavirus neutralization and COVID‐19 severity

The virus severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), responsible for the global coronavirus disease‐2019 (COVID‐19) pandemic, spread rapidly around the world causing high morbidity and mortality. However, there are four known, endemic seasonal coronaviruses in humans (HCoVs), and...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wells, David A., Cantoni, Diego, Mayora‐Neto, Martin, Genova, Cecilia Di, Sampson, Alexander, Ferrari, Matteo, Carnell, George, Nadesalingam, Angalee, Smith, Peter, Chan, Andrew, Raddi, Gianmarco, Castillo‐Olivares, Javier, Baxendale, Helen, Temperton, Nigel, Heeney, Jonathan L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9349487/ https://www.ncbi.nlm.nih.gov/pubmed/35705514 http://dx.doi.org/10.1002/jmv.27937

Ejemplares similares

Neutralisation Hierarchy of SARS-CoV-2 Variants of Concern Using Standardised, Quantitative Neutralisation Assays Reveals a Correlation With Disease Severity; Towards Deciphering Protective Antibody Thresholds
por: Cantoni, Diego, et al.
Publicado: (2022)

Coronavirus Pseudotypes for All Circulating Human Coronaviruses for Quantification of Cross-Neutralizing Antibody Responses
por: Sampson, Alexander Thomas, et al.
Publicado: (2021)

Pseudotyped Bat Coronavirus RaTG13 is efficiently neutralised by convalescent sera from SARS-CoV-2 infected patients
por: Cantoni, Diego, et al.
Publicado: (2022)

Paucity and discordance of neutralising antibody responses to SARS-CoV-2 VOCs in vaccinated immunodeficient patients and health-care workers in the UK
por: Nadesalingam, Angalee, et al.
Publicado: (2021)

Vaccination and protective immunity to SARS-CoV-2 omicron variants in people with immunodeficiencies
por: Nadesalingam, Angalee, et al.
Publicado: (2023)

Differential T-cell and antibody responses induced by mRNA versus adenoviral vectored COVID-19 vaccines in patients with immunodeficiencies
por: Aguinam, Ernest T., et al.
Publicado: (2023)

The role of pseudotype neutralization assays in understanding SARS CoV-2
por: Cantoni, Diego, et al.
Publicado: (2021)

Analysis of Serological Biomarkers of SARS-CoV-2 Infection in Convalescent Samples From Severe, Moderate and Mild COVID-19 Cases
por: Castillo-Olivares, Javier, et al.
Publicado: (2021)

Analysis of Antibody Neutralisation Activity against SARS-CoV-2 Variants and Seasonal Human Coronaviruses NL63, HKU1, and 229E Induced by Three Different COVID-19 Vaccine Platforms
por: Cantoni, Diego, et al.
Publicado: (2022)

Correlation between pseudotyped virus and authentic virus neutralisation assays, a systematic review and meta-analysis of the literature
por: Cantoni, Diego, et al.
Publicado: (2023)

Glycan masking of a non-neutralising epitope enhances neutralising antibodies targeting the RBD of SARS-CoV-2 and its variants
por: Carnell, George W., et al.
Publicado: (2023)

Pseudotype-Based Neutralization Assays for Influenza: A Systematic Analysis
por: Carnell, George William, et al.
Publicado: (2015)

Correlation of Influenza B Haemagglutination Inhibiton, Single-Radial Haemolysis and Pseudotype-Based Microneutralisation Assays for Immunogenicity Testing of Seasonal Vaccines
por: Carnell, George W., et al.
Publicado: (2021)

Influenza A (N1-N9) and Influenza B (B/Victoria and B/Yamagata) Neuraminidase Pseudotypes as Tools for Pandemic Preparedness and Improved Influenza Vaccine Design
por: da Costa, Kelly A. S., et al.
Publicado: (2022)

Capture and inactivation of viral particles from bioaerosols by electrostatic precipitation
por: Preston, Hannah E., et al.
Publicado: (2023)

AutoPlate: Rapid Dose-Response Curve Analysis for Biological Assays
por: Palmer, Phil, et al.
Publicado: (2022)

Detection of Serum Cross-Reactive Antibodies and Memory Response to SARS-CoV-2 in Prepandemic and Post–COVID-19 Convalescent Samples
por: Shrwani, Khalid, et al.
Publicado: (2021)

Chimeric influenza haemagglutinins: Generation and use in pseudotype neutralization assays
por: Ferrara, Francesca, et al.
Publicado: (2016)

Pseudotype Neutralization Assays: From Laboratory Bench to Data Analysis
por: Ferrara, Francesca, et al.
Publicado: (2018)

Novel intranasal vaccine targeting SARS-CoV-2 receptor binding domain to mucosal microfold cells and adjuvanted with TLR3 agonist Riboxxim™ elicits strong antibody and T-cell responses in mice
por: Horvath, Dennis, et al.
Publicado: (2023)

Critical Care Workers Have Lower Seroprevalence of SARS-CoV-2 IgG Compared with Non-patient Facing Staff in First Wave of COVID19
por: Baxendale, Helen E., et al.
Publicado: (2021)

Longitudinally Profiling Neutralizing Antibody Response to SARS Coronavirus with Pseudotypes
por: Temperton, Nigel J., et al.
Publicado: (2005)

Antibody correlates of protection from SARS-CoV-2 reinfection prior to vaccination: A nested case-control within the SIREN study
por: Atti, Ana, et al.
Publicado: (2022)

Durable T-cellular and humoral responses in SARS-CoV-2 hospitalized and community patients
por: Mohn, Kristin G.-I., et al.
Publicado: (2022)

Exploiting Pan Influenza A and Pan Influenza B Pseudotype Libraries for Efficient Vaccine Antigen Selection
por: Del Rosario, Joanne Marie M., et al.
Publicado: (2021)

Development of a Clinical MALDI-ToF Mass Spectrometry Assay for SARS-CoV-2: Rational Design and Multi-Disciplinary Team Work
por: Iles, Ray K., et al.
Publicado: (2020)

Studying longitudinal neutralising antibody levels against Equid herpesvirus 1 in experimentally infected horses using a novel pseudotype based assay
por: Genova, Cecilia Di, et al.
Publicado: (2023)

Different decay of antibody response and VOC sensitivity in naïve and previously infected subjects at 15 weeks following vaccination with BNT162b2
por: Siracusano, Gabriel, et al.
Publicado: (2022)

The Use of Hyperimmune Chicken Reference Sera Is Not Appropriate for the Validation of Influenza Pseudotype Neutralization Assays
por: Ferrara, Francesca, et al.
Publicado: (2017)

The Use of Retroviral Pseudotypes for the Measurement of Antibody Responses to SARS Coronavirus
por: Temperton, Nigel James
Publicado: (2009)

Multiplex Evaluation of Influenza Neutralizing Antibodies with Potential Applicability to In-Field Serological Studies
por: Molesti, Eleonora, et al.
Publicado: (2014)

Complement Activation-Independent Attenuation of SARS-CoV-2 Infection by C1q and C4b-Binding Protein
por: Beirag, Nazar, et al.
Publicado: (2023)

Human surfactant protein D facilitates SARS-CoV-2 pseudotype binding and entry in DC-SIGN expressing cells, and downregulates spike protein induced inflammation
por: Beirag, Nazar, et al.
Publicado: (2022)

SARS-CoV-2 Spike Protein Stabilized in the Closed State Induces Potent Neutralizing Responses
por: Carnell, George W., et al.
Publicado: (2021)

Nanobodies mapped to cross-reactive and divergent epitopes on A(H7N9) influenza hemagglutinin using yeast display
por: Gaiotto, Tiziano, et al.
Publicado: (2021)

Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison
por: Wright, Edward, et al.
Publicado: (2008)

Type I feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines
por: Dye, Charlotte, et al.
Publicado: (2007)

Humoral and cellular immune responses to Lassa fever virus in Lassa fever survivors and their exposed contacts in Southern Nigeria
por: Ugwu, Chinedu, et al.
Publicado: (2022)

Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination Boosts Neutralizing Activity Against Seasonal Human Coronaviruses
por: Lawrenz, Jan, et al.
Publicado: (2022)

Cross-Reactive and Lineage-Specific Single Domain Antibodies against Influenza B Hemagglutinin
por: Ramage, Walter, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_1vg4brm6sls9ri5dfjlus5lmi1